Dieniffer Peixoto-Neves1,2, Qian Wang1, Jose H Leal-Cardoso2, Luciana V Rossoni3, Jonathan H Jaggar1. 1. Department of Physiology, University of Tennessee Health Science Center, Memphis, TN, USA. 2. Laboratório de Eletrofisiologia, Instituto Superior de Ciências Biomédicas, Universidade Estadual do Ceará, Fortaleza, Ceará, Brazil. 3. Laboratório de Fisiologia Vascular, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil.
Abstract
BACKGROUND AND PURPOSE: Eugenol, a vanilloid molecule found in some dietary plants, relaxes vasculature in part via an endothelium-dependent process; however, the mechanisms involved are unclear. Here, we investigated the endothelial cell-mediated mechanism by which eugenol modulates rat mesenteric artery contractility and systemic BP. EXPERIMENTAL APPROACH: The isometric tension of rat mesenteric arteries (size 200-300 μm) was measured using wire myography; non-selective cation currents (ICat ) were recorded in endothelial cells using patch clamp electrophysiology. Mean arterial pressure (MAP) and heart rate (HR) were determined in anaesthetized rats. KEY RESULTS: Eugenol relaxed endothelium-intact arteries in a concentration-dependent manner and this effect was attenuated by endothelium denudation. L-NAME, a NOS inhibitor, a combination of TRAM-34 and apamin, selective blockers of intermediate and small conductance Ca(2+) -activated K(+) channels, respectively, and HC-067047, a TRPV4 channel inhibitor, but not indomethacin, a COX inhibitor, reduced eugenol-induced relaxation in endothelium-intact arteries. Eugenol activated HC-067047-sensitive ICat in mesenteric artery endothelial cells. Short interfering RNA (siRNA)-mediated TRPV4 knockdown abolished eugenol-induced ICat activation. An i.v. injection of eugenol caused an immediate, transient reduction in both MAP and HR, which was followed by prolonged, sustained hypotension in anaesthetized rats. This sustained hypotension was blocked by HC-067047. CONCLUSIONS AND IMPLICATIONS: Eugenol activates TRPV4 channels in mesenteric artery endothelial cells, leading to vasorelaxation, and reduces systemic BP in vivo. Eugenol may be therapeutically useful as an antihypertensive agent and is a viable molecular candidate from which to develop second-generation TRPV4 channel activators that reduce BP.
BACKGROUND AND PURPOSE:Eugenol, a vanilloid molecule found in some dietary plants, relaxes vasculature in part via an endothelium-dependent process; however, the mechanisms involved are unclear. Here, we investigated the endothelial cell-mediated mechanism by which eugenol modulates rat mesenteric artery contractility and systemic BP. EXPERIMENTAL APPROACH: The isometric tension of rat mesenteric arteries (size 200-300 μm) was measured using wire myography; non-selective cation currents (ICat ) were recorded in endothelial cells using patch clamp electrophysiology. Mean arterial pressure (MAP) and heart rate (HR) were determined in anaesthetized rats. KEY RESULTS:Eugenol relaxed endothelium-intact arteries in a concentration-dependent manner and this effect was attenuated by endothelium denudation. L-NAME, a NOS inhibitor, a combination of TRAM-34 and apamin, selective blockers of intermediate and small conductance Ca(2+) -activated K(+) channels, respectively, and HC-067047, a TRPV4 channel inhibitor, but not indomethacin, a COX inhibitor, reduced eugenol-induced relaxation in endothelium-intact arteries. Eugenol activated HC-067047-sensitive ICat in mesenteric artery endothelial cells. Short interfering RNA (siRNA)-mediated TRPV4 knockdown abolished eugenol-induced ICat activation. An i.v. injection of eugenol caused an immediate, transient reduction in both MAP and HR, which was followed by prolonged, sustained hypotension in anaesthetized rats. This sustained hypotension was blocked by HC-067047. CONCLUSIONS AND IMPLICATIONS: Eugenol activates TRPV4 channels in mesenteric artery endothelial cells, leading to vasorelaxation, and reduces systemic BP in vivo. Eugenol may be therapeutically useful as an antihypertensive agent and is a viable molecular candidate from which to develop second-generation TRPV4 channel activators that reduce BP.
Authors: Suelhem A Mendoza; Juan Fang; David D Gutterman; David A Wilcox; Aaron H Bubolz; Rongshan Li; Makoto Suzuki; David X Zhang Journal: Am J Physiol Heart Circ Physiol Date: 2009-12-04 Impact factor: 4.733
Authors: David X Zhang; Suelhem A Mendoza; Aaron H Bubolz; Atsuko Mizuno; Zhi-Dong Ge; Rongshan Li; David C Warltier; Makoto Suzuki; David D Gutterman Journal: Hypertension Date: 2009-02-02 Impact factor: 10.190
Authors: Scott Earley; Thierry Pauyo; Rebecca Drapp; Matthew J Tavares; Wolfgang Liedtke; Joseph E Brayden Journal: Am J Physiol Heart Circ Physiol Date: 2009-07-17 Impact factor: 4.733
Authors: J Saliez; C Bouzin; G Rath; P Ghisdal; F Desjardins; R Rezzani; L F Rodella; J Vriens; B Nilius; O Feron; J-L Balligand; C Dessy Journal: Circulation Date: 2008-02-11 Impact factor: 29.690
Authors: Jay S Naik; Jessica M Osmond; Benjimen R Walker; Nancy L Kanagy Journal: Am J Physiol Heart Circ Physiol Date: 2016-10-07 Impact factor: 4.733
Authors: W Kyle Martin; Alan H Tennant; Rory B Conolly; Katya Prince; Joey S Stevens; David M DeMarini; Brandi L Martin; Leslie C Thompson; M Ian Gilmour; Wayne E Cascio; Michael D Hays; Mehdi S Hazari; Stephanie Padilla; Aimen K Farraj Journal: Sci Rep Date: 2019-01-15 Impact factor: 4.379
Authors: Gerald Wölkart; Alexander Kollau; Heike Stessel; Michael Russwurm; Doris Koesling; Astrid Schrammel; Kurt Schmidt; Bernd Mayer Journal: PLoS One Date: 2019-09-09 Impact factor: 3.240